Genmab (GMAB) has released an update.
Genmab A/S, the Danish biotechnology firm, is actively executing its share buy-back program, with the aim to repurchase up to DKK 3.5 billion worth of shares by December 16, 2024. Recent transactions under this program have resulted in the acquisition of 34,333 shares for a total value of DKK 68,931,908.30, contributing to Genmab now holding 2.38% of its total share capital as treasury shares. The company is renowned for its innovative antibody therapeutics and strategic partnerships aimed at transforming the lives of patients with serious diseases.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
